Zydus Lifesciences hits 52-week high on getting USFDA’s final approval for Roflumilast Tablets

Zydus Lifesciences hits 52-week high on getting USFDA’s final approval for Roflumilast Tablets

by 5paisa Research Team Last Updated: Apr 19, 2023 - 05:45 pm 1k Views
Listen icon

Today, the stock opened at Rs 519.70 and touched a high and low of Rs 519.70 and Rs 513.60, respectively. 

Approval from USFDA 

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Roflumilast Tablets, 250 mcg (USRLD: Daliresp Tablets, 250 mcg). 

Roflumilast reduces inflammation in the lungs which leads to chronic obstructive pulmonary disease (COPD). It is used to prevent the worsening of symptoms in people with severe COPD. The drug will be manufactured at the group’s formulation manufacturing facility in SEZ Ahmedabad, (India). 

Roflumilast Tablets, 250 mcg had annual sales of USD 34 million in the United States (IQVIA MAT February 2023). The group now has 363 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04. 

Stock price movement 

On Wednesday, the shares of Zydus Lifesciences closed at its 52-week high at Rs 517.30, up by 0.30% from its previous closing of Rs 515.75 on the BSE. The stock opened at Rs 519.70 and touched a high and low of Rs 519.70 and Rs 513.60, respectively. 

The BSE group 'A' stock of face value of Rs 1 touched a 52-week high and low of Rs 519.70 and Rs 319.40, respectively. Last one week high and low of the scrip stood at Rs 519.70 and Rs 499.50respectively. The current market cap of the company is Rs 52,361.32 crore. 

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 17.02% and 8.00% respectively. 

Company Profile 

Zydus Lifesciences is one of the top five players in the domestic formulations market, and domestic sales formed 32% of consolidated revenue in fiscal 2022. The group is ranked among the top 3 players in the high-growth segments such as respiratory, pain management, gynaecology and dermatology, which account for about 11%, 10%, 6% and 5%, respectively, of its domestic formulation sales. 

Share Market Today


How do you rate this article?

Start Investing in 5 mins*

Rs. 20 Flat Per Order | 0% Brokerage

378X91-D3

About the Author

Our research team is composed of some highly qualified research professionals, their expertise range across sectors.

Disclaimer

Investment/Trading in securities Market is subject to market risk, past performance is not a guarantee of future performance. The risk of loss in trading and investment in Securities markets including Equites and Derivatives can be substantial.
Enjoy 0%* Brokerage with 5paisa
Resend OTP
Please Enter OTP
Mobile No. belongs to

By proceeding, you agree to the T&C.

Latest News
Trust Fintech IPO Subscribed 108.63 times

Trust Fintech IPO is book-built issue of ₹63.45 crores, consisting entirely of fresh issue shares totalling 62.82 lakh. Trust Fintech IPO commenced its subscription period on March 26, 2024, & concludes today, March 28, 2024.

Aspire & Innovative IPO Subscribed 15.17 times

Aspire & Innovative IPO is a book built issue of Rs 21.97 crores. The issue comprises entirely a fresh issue of 40.68 lakh shares. Aspire & Innovative IPO opens for subscription on March 26, 2024, and closes on March 28, 2024. The allotment for the Aspire & Innovative IPO is expected to be finalized on Monday, April 1, 2024.

Blue Pebble IPO Subscribed 56.32 times

Blue Pebble IPO, valued at ₹18.14 crores, comprises fresh issue of 10.8 lakh shares. Commencing subscription on March 26, 2024, Blue Pebble IPO is set to conclude on March 28, 2024. Allotment process is scheduled to be finalized by Monday, April 1, 2024. Following this, IPO is slated to debut on NSE SME, with tentative listing date of Wednesday, April 3, 2024.